Natera Announces the Appointment of Gail Marcus as Member of the Board of Directors
Experienced Healthcare Executive Adds Deep Experience in Managed Care and Market Access
SAN CARLOS, Calif., May 4, 2017 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, announced today the appointment of Gail Marcus as member of the board of directors, effective March 2017.
Ms. Marcus has served as a consultant and practice leader in the healthcare consulting practice of Exceptional Leaders International since 2015. She is currently Assistant Professor and Director of the Global Healthcare Management and Biomedical Informatics programs at the Massachusetts College of Pharmacy and Health Sciences.
Ms. Marcus served as president and chief executive officer of Caris Diagnostics. (also known as Pathology Partners, Inc.) and has held a variety of leadership roles in her career with diagnostics, pharmacy benefit management and managed care companies, including Caremark, UnitedHealthcare, and Cigna. Ms. Marcus currently serves on the Centers for Medicare & Medicaid Services Advisory Panel on Clinical Diagnostic Laboratory Tests.
"We are pleased to welcome Gail to our board of directors and greatly value her more than 25 years of experience managing and growing domestic and international healthcare businesses," said Natera CEO and founder, Matthew Rabinowitz, Ph.D. "We value her deep experience in managed care and look forward to her counsel as we continue to expand our business and provide patients with greater access to our genetic testing services."
Ms. Marcus holds Bachelor of Arts degrees in Spanish and in Mathematics from Wesleyan University, an M.S.E. in Computer and Information Sciences from the University of Pennsylvania Moore School of Engineering, an M.B.A. from the Wharton School of the University of Pennsylvania, and is pursuing a Doctorate of Health Administration from the Medical University of South Carolina.
Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system.
Product offerings include the Spectrum® pre-implantation genetic test for embryo selection during IVF; the Anora® miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier test to detect inherited mutations; the Panorama® non-invasive prenatal test (NIPT) to identify common chromosomal anomalies in a fetus as early as nine weeks of gestation; and Evercord™, a cord blood and tissue banking service offered at birth to expectant parents. Each test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test.
These tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration.
This release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. Any forward-looking statements contained in this press release are based upon Natera’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release.
Subsequent events may cause these expectations to change, and Natera disclaims any obligation to update the forward-looking statements for any reason after the date of this press release. These forward-looking statements are subject to a number of known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to increase the use and adoption of our tests and to develop and commercialize new product offerings, our ability to successfully increase demand for and grow revenues for our product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers, or our ability to expand or maintain third-party payer coverage and reimbursement for our tests.
Additional risks and uncertainties are discussed in greater detail in the sections entitled "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in Natera’s Form 10-K for the year ended December 31, 2016. Further information on potential risks that could affect actual results will be included in other filings Natera makes with the SEC from time to time. These documents are available for free on the company’s website at http://www.natera.com in the Investor Relations section, and on the SEC’s website at www.sec.gov.
Mike Brophy, Chief Financial Officer, 650-249-9091 x1471
Laura Zobkiw, Corporate and Media Relations, 650-249-9091 x1649
SOURCE Natera, Inc.